A Phase 2 interventional study of FCN-338 + Azacitidine and FCN-338 + erythromycin+ Ara-C in Safety, Antitumor Activity and PK Profile, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 113th largest by enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2023, is one of 105 in phase 2, reaches primary completion later than 21 of the 90 other live ones, and was the 181st registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 133 · Phase 3 31 · Phase 4 3
First in 2000; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 211 interventional studies. Of the 100 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 214 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., one of the names counted as Fosun Pharma. Under that name alone:
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. is the lead sponsor of 35 studies on the registry; 22 are open to participants now.
Fosun Pharma has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
25 of the studies testing azacitidine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT07514936Phase 3Chinese PLA General HospitalVenetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia | 2027-09-30 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT06783790Institute of Hematology & Blood Diseases Hospital, ChinaAvapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | 2026-12 |
| NCT06066905Guangdong Provincial People's HospitalA Study of Chidamide With AZA in MRD Positive AML After Transplant | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, multicenter study to safety \& tolerability, antitumor activity, and pharmacokinetics of FCN-338 in Combination with szacitidine (AZA) or chemotherapy(erythromycin, cytarabine(Ara-C)) in Patients with myeloid neoplasms
Primary Objectives:1.To assess the safety and tolerability of FCN-338 in combination with AZA or chemotherapy in patients with myeloid neoplasms. 2. To explore the antitumor activity of FCN-338 combination therapy in patients with myeloid neoplasms.
Secondary Objectives: 1. To assess the pharmacokinetic profile of the FCN-338 combination therapy in patients with myeloid neoplasms.2. To assess the transfusion independence rate in patients with myeloid neoplasms.
There were 2 cohorts based on different combination therapies and different indications.
Cohort A is FCN-338 combined with AZA (75mg/m², SC, QD, D1-7) for the treatment in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.
Cohort B is FCN-338 combined with intensive chemotherapy for first line (1L) fit AML patients. During the induction phase, patients will be treated with erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7). Patients achieving partial remission (PR) will repeat induction phase once, and patients who do not reach PR after first cycle of induction phase and those who do not achieve complete remission (CR)/Complete remission with incomplete hematological recovery (CRi)/morphologic leukemia-free state (MLFS) after two cycles of induction phase will receive other new antitumor treatments. Patients who achieve CR/CRi/MLFS will undergo consolidation phase with medium- to high-dose Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles, with the exact dose and number of cycles determined by investigator. Patients with intermediate- to high-risk according to the 2017 European Leukemia Net (ELN) stratification will undergo a total of 24 cycles of maintenance phase after completion of consolidation phase. Maintenance phase will consist of 24 cycles, FCN-338 in combination with AZA (50 mg/m², d1-5) for the first 12 cycles and FCN-338 alone for the rest 12 cycles. FCN-338 will be administered once daily (QD), D1-14 per cycle during induction phase, consolidation phase and maintenance phase.
Inclusive Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: FCN-338 + Azacitidine
Combination Product: FCN-338 + erythromycin+ Ara-C
Drug pages: Bcl-2 Inhibitor LOXO-338 · Azacitidine
FCN-338 (400 or 600 mg, PO, QD, D1-28) combined with azacitidine (75mg/m², SC, QD, D1-7), 28 days/cycle
Drug pages: Bcl-2 Inhibitor LOXO-338 · Erythromycin · Cytarabine
Induction phase: FCN-338(600 mg, QD, D1-14) , erythromycin (60 mg/m², IV, QD , D1-3) and Ara-C (100 mg/m², IV, QD, D1-7) for 1 to 2 cycles. Consolidation phase: FCN-338(600 mg, QD, D1-14) ,Ara-C (1 to 3 g/m²/12h, 6 doses) for 3 to 4 cycles Maintenance phase:FCN-338(600 mg, QD, D1-14) , azacitidine (50 mg/m², SC, QD, D1-5) for the first 12 cycles and FCN-338 (600 mg, QD, D1-14) alone for the rest 12 cycles
Incidence of DLT
Incidence of DLT in DLT observation period
Time frame: At the end of Cycle 1 (each cycle is 28 days)
Title: composite CR rate (CRc)
The proportion of CR, CRi and MLFS patients in the efficacy analysis set (EAS)
Time frame: From the first dose to the end of maintenance phase, assessed up to 30 months
Minimal residual disease (MRD) negative rate
The proportion of AML patients with CR/CRi/MLFS who were negative for MRD.
Time frame: From the first dose to the end of maintenance phase, assessed up to 30 months
Transfusion Independence
The proportion of independence on red blood cell (RBC) and platelet transfusions among those patients who were dependent on RBC and platelet transfusions at baseline.
Time frame: From the first dose to the end of maintenance phase, assessed up to 30 months
Time to remission
Defined as the time from the first dose to the first observation of CR/CRi/MLFS
Time frame: From the first dose to the first observation of CR/CRi/MLFS, assessed up to 2 months
Event-free survival
Defined as the time from the first dose to induction failure or relapse or death from any cause (whichever occours first).
Time frame: From the first dose to induction failure or relapse or death from any cause (whichever occours first), assessed up to 54 months
Duration of remission
Defined as the time from the first observation of CR/CRi/MLFS to tumor progression or death from any cause(whichever occours first).
Time frame: From the first observation of CR/CRi/MLFS to tumor progression or death from any cause(whichever occours first), assessed up to 54 months
Overall survival
Defined as the time from the first dose to death from any cause.
Time frame: From the first dose to 30 days after the last dose or the initiation of new antitumor therapy (whichever occours first), assessed up to 30 months
Incidence of treatment-emergent adverse events(TEAEs) and treatment-related adverse events (TRAEs) [Safety and Tolerability]
Safety will be evaluated by summarizing DLT, AE, changes in laboratory findings, and changes in vital signs. Adverse events will be summarized for the DLT observation period and the entire treatment period based on the DLT analysis set and the safety analysis set, respectively, and drug-related AEs, SAEs, AEs of toxicity grade ≥3, and AEs leading to discontinuation will be counted. The occurrence of DLT will be assessed specifically for the DLT analysis set.
Time frame: From the first dose to 30 days after the last dose or the initiation of new antitumor therapy (whichever occours first).
Cmax of FCN-338
Pharmacokinetics of FCN-338 by assesment of the maximum plasma concentration
Time frame: Up to 24 hours postdose
AUC0-t of FCN-338
Pharmacokinetics of FCN-338 by assesment of the Area Under The Plasma Concentration Time Curve From Time 0 To The Time Of The Last Quantifiable Concentration
Time frame: Up to 24 hours postdose
AUC0-24 of FCN-338
Pharmacokinetics of FCN-338 by assesment of the Area Under The Plasma Concentration Time Curve From Time 0 To The 24 hours postdose
Time frame: Up to 24 hours postdose
AUC0-∞ of FCN-338
Pharmacokinetics of FCN-338 by assesment of The Plasma Concentration Time Curve From Time 0 To Infinity
Time frame: Up to 24 hours postdose
Tmax of FCN-338
Pharmacokinetics of FCN-338 by assesment of Time To Maximum Observed Plasma Concentration
Time frame: Up to 24 hours postdose
t1/2 of FCN-338
Pharmacokinetics of FCN-338 by assesment of Terminal Half-life
Time frame: Up to 24 hours postdose
CL/F of FCN-338
Pharmacokinetics of FCN-338 by assesment of Apparent Clearance Of Drug From Plasma After Oral Administration
Time frame: Up to 24 hours postdose
Vd/F of FCN-338
Pharmacokinetics of FCN-338 by assesment of Apparent Volume Of Distribution
Time frame: Up to 24 hours postdose
Css_max of FCN-338
Pharmacokinetics of FCN-338 by assesment of Maximum Observed Plasma Concentration At Steady State
Time frame: Up to 24 hours postdose
Css_av of FCN-338
Pharmacokinetics of FCN-338 by assesment of the Average concentration At Steady State
Time frame: Up to 24 hours postdose
AUCss of FCN-338
Pharmacokinetics of FCN-338 by assesment of the Area Under The Plasma Concentration Time Curve within dosing interval At Steady State
Time frame: Up to 24 hours postdose
DF of FCN-338
Pharmacokinetics of FCN-338 by assesment of fluctuation
Time frame: Up to 24 hours postdose
MRT
Pharmacokinetics of FCN-338 by assesment of Mean residence time
Time frame: Up to 24 hours postdose
Kel of FCN-338
Pharmacokinetics of FCN-338 by assesment of the Terminal rate constant.
Time frame: Up to 24 hours postdose
Css_min of FCN-338
Pharmacokinetics of FCN-338 by assesment of Trough Concentration At Steady State
Time frame: Up to 24 hours postdose
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's planned 39 months is close to that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bcl-2 Inhibitor LOXO-338 · Azacitidine · Erythromycin · Cytarabine
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. →